CRISPR Therapeutics AG — Director's Dealing 2019

Jan 3, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2019-01-02

Reporting Person: Klein Lawrence Otto (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-01-02	Restricted Stock Units	A	20000	$29.87	Acquired	20000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-02	Stock Option (Right to Buy)	$29.87	A	20000	Acquired	2029-01-01	Common Shares (20000)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one CRSP common share.

F2: The restricted stock units shall vest in full on January 2, 2021, subject to continued employment with the company.

F3: 25% of the option shall vest on January 2, 2020, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the final day of each month.